{ "run": { "id": "cmnr13c360396p658bwt8lhuw", "region": "US", "assetId": "cmnr13c2k038vp658yhbsro7x", "ticker": "DHR", "snapshotId": "cmnr13c2p0392p658mv1bnih1", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:20:25.839Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr13c2p0392p658mv1bnih1", "assetId": "cmnr13c2k038vp658yhbsro7x", "asOf": "2026-04-08T20:00:03.000Z", "snapshot": { "asOf": "2026-04-08T20:00:03.000Z", "quote": { "asOf": "2026-04-08T20:00:03.000Z", "open": null, "price": 196.19, "dayLow": 195, "volume": 2142553, "dayHigh": 198.56, "currency": "USD", "prevClose": 191.01, "week52Low": 171, "week52High": 242.8 }, "fundamentals": { "pe": 45.1518737672584, "beta": 0.911845733533749, "epsTTM": 5.07, "fcfTTM": 5125000000, "growth": { "epsYoy": -0.04878048780487801, "revenueYoy": 0.0290261780104712 }, "sector": "Industrial Instruments For Measurement, Display, and Control", "margins": { "net": 0.1471019211983067, "gross": 0.5911348095083034, "operating": 0.1908987300553566 }, "website": null, "industry": null, "pegRatio": -9.25613412228798, "ebitdaTTM": 5829000000, "forwardPe": 27.2199762187872, "marketCap": 125900000000, "totalCash": 4615000000, "totalDebt": 18420000000, "debtEquity": 0.350630068146343, "quickRatio": 1.252827971206111, "revenueTTM": 24568000000, "companyName": "DANAHER CORP /DE/", "priceToBook": 2.12832858056016, "currentRatio": 1.873953283384751, "dividendYield": 0.00538150836741193, "returnOnAssets": 0.04330010543467842, "returnOnEquity": 0.0687935432291468, "analystOpinions": null, "businessSummary": null, "enterpriseValue": 176956284000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": null, "sharesOutstanding": 707139356, "enterpriseToEbitda": 30.35791456510551, "analystTargetMedian": null, "enterpriseToRevenue": 7.202714262455227, "operatingCashflowTTM": 6416000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:20:25.825Z" }, "results": [ { "id": "cmnr13c380398p658cw9w9k2j", "runId": "cmnr13c360396p658bwt8lhuw", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"DHR\",\"currency\":\"USD\",\"current_price\":196.19,\"target_price_6m\":200,\"target_price_12m\":207,\"recommendation\":\"HOLD\",\"confidence\":0.57,\"thesis_bullets\":[\"Premium life-sciences franchise with strong DBS-driven margin culture\",\"Bioprocessing recovery remains gradual, limiting near-term revenue acceleration\",\"Valuation at 30x EV/EBITDA prices in significant future growth already\",\"FCF generation robust at ~$5.1B TTM supporting deleveraging and M&A optionality\",\"Mixed EPS trajectory with YoY decline constrains re-rating catalyst timeline\"],\"key_drivers\":[{\"driver\":\"Bioprocessing order recovery pace\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Forward PE of 27x implies EPS recovery already priced in\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Danaher Business System driving operational efficiency\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Diagnostics volumes normalizing post-COVID\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"M&A pipeline leveraging strong balance sheet\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"High net debt ~$13.8B limiting financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Recurring revenue mix increasing across segments\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Biotech funding environment improving gradually\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"FX headwinds from strong USD\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Bioprocessing destocking extends further than expected, delaying recovery\",\"Multiple compression if growth doesn't accelerate to justify premium valuation\",\"Large acquisition integration risk eroding returns\",\"Biotech funding slowdown reducing customer capital spending\",\"Interest rate environment pressuring growth multiples\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.22,\"wacc\":0.085,\"terminal_multiple\":25},\"scenarios\":{\"bear\":{\"target_price\":165,\"prob\":0.25,\"notes\":\"Bioprocessing stagnation and multiple compression to 22x EBITDA.\"},\"base\":{\"target_price\":207,\"prob\":0.50,\"notes\":\"Gradual bioprocessing recovery, margins expand modestly, multiple holds.\"},\"bull\":{\"target_price\":245,\"prob\":0.25,\"notes\":\"Accelerating bioprocessing orders plus accretive M&A drive re-rating.\"}},\"method_notes\":\"Blended EV/EBITDA and forward PE approach anchored on normalized earnings power. Revenue CAGR of 5% assumes gradual bioprocessing recovery. At 196 current price sits near fair value given 30x EV/EBITDA vs. mid-single-digit organic growth. 12M base target of 207 (~5.5% upside) supports HOLD given mixed near-term signals. Sell-side targets noted but not used as inputs. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "ai-equity-research-v1", "risks": [ "Bioprocessing destocking extends further than expected, delaying recovery", "Multiple compression if growth doesn't accelerate to justify premium valuation", "Large acquisition integration risk eroding returns", "Biotech funding slowdown reducing customer capital spending", "Interest rate environment pressuring growth multiples" ], "ticker": "DHR", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual bioprocessing recovery, margins expand modestly, multiple holds.", "target_price": 207 }, "bear": { "prob": 0.25, "notes": "Bioprocessing stagnation and multiple compression to 22x EBITDA.", "target_price": 165 }, "bull": { "prob": 0.25, "notes": "Accelerating bioprocessing orders plus accretive M&A drive re-rating.", "target_price": 245 } }, "confidence": 0.57, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 25, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Bioprocessing order recovery pace", "impact": "HIGH", "direction": "POS" }, { "driver": "Forward PE of 27x implies EPS recovery already priced in", "impact": "HIGH", "direction": "NEG" }, { "driver": "Danaher Business System driving operational efficiency", "impact": "MED", "direction": "POS" }, { "driver": "Diagnostics volumes normalizing post-COVID", "impact": "MED", "direction": "NEG" }, { "driver": "M&A pipeline leveraging strong balance sheet", "impact": "MED", "direction": "POS" }, { "driver": "High net debt ~$13.8B limiting financial flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Recurring revenue mix increasing across segments", "impact": "MED", "direction": "POS" }, { "driver": "Biotech funding environment improving gradually", "impact": "HIGH", "direction": "POS" }, { "driver": "FX headwinds from strong USD", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended EV/EBITDA and forward PE approach anchored on normalized earnings power. Revenue CAGR of 5% assumes gradual bioprocessing recovery. At 196 current price sits near fair value given 30x EV/EBITDA vs. mid-single-digit organic growth. 12M base target of 207 (~5.5% upside) supports HOLD given mixed near-term signals. Sell-side targets noted but not used as inputs. Not investment advice.", "current_price": 196.19, "recommendation": "HOLD", "thesis_bullets": [ "Premium life-sciences franchise with strong DBS-driven margin culture", "Bioprocessing recovery remains gradual, limiting near-term revenue acceleration", "Valuation at 30x EV/EBITDA prices in significant future growth already", "FCF generation robust at ~$5.1B TTM supporting deleveraging and M&A optionality", "Mixed EPS trajectory with YoY decline constrains re-rating catalyst timeline" ], "target_price_6m": 200, "target_price_12m": 207 }, "errorsJson": { "attempts": [ { "error": "sanity_error: hold_target_too_directional: HOLD requires implied 12M return within +/-6%.", "attempt": 0, "rawOutputTruncated": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"DHR\",\"currency\":\"USD\",\"current_price\":196.19,\"target_price_6m\":201,\"target_price_12m\":208,\"recommendation\":\"HOLD\",\"confidence\":0.58,\"thesis_bullets\":[\"Premium life-sciences franchise with strong DBS-driven margin culture\",\"Bioprocessing recovery remains gradual, limiting near-term revenue acceleration\",\"Valuation at 30x EV/EBITDA prices in significant future growth already\",\"FCF generation robust at ~$5.1B TTM supporting deleveraging and M&A optionality\",\"Mixed EPS trajectory with YoY decline constrains re-rating catalyst timeline\"],\"key_drivers\":[{\"driver\":\"Bioprocessing order recovery pace\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Forward PE of 27x implies EPS recovery already priced in\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Danaher Business System driving operational efficiency\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Diagnostics volumes normalizing post-COVID\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"M&A pipeline leveraging strong balance sheet\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"High net debt of ~$13.8B limiting financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},…" } ], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 15622, "createdAt": "2026-04-09T05:20:25.839Z", "usage": { "inputTokens": 4108, "outputTokens": 911, "costUsd": 0.043315 } }, { "id": "cmnr13c38039bp658c6js5j9w", "runId": "cmnr13c360396p658bwt8lhuw", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"equity_research_analyst\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"DHR\",\n \"currency\": \"USD\",\n \"current_price\": 196.19,\n \"target_price_6m\": 198.0,\n \"target_price_12m\": 200.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Strong cash flow supports financial flexibility.\",\n \"Diversified portfolio mitigates sector-specific risks.\",\n \"High valuation multiples limit near-term upside.\",\n \"Recent EPS decline indicates growth challenges.\",\n \"Acquisition strategy could enhance long-term earnings.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Revenue growth from new products\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Margin improvement through efficiencies\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Successful acquisition integration\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Economic downturn impacting demand\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Currency exchange rate volatility\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory changes in key markets\", \"impact\": \"HIGH\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Execution risk in mergers and acquisitions\",\n \"Contraction of valuation premiums\",\n \"Macroeconomic slowdown reducing demand\",\n \"Increased competitive pressures\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.2,\n \"wacc\": 0.085,\n \"terminal_multiple\": 20.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 180.0, \"prob\": 0.2, \"notes\": \"Weak growth and multiple compression.\" },\n \"base\": { \"target_price\": 200.0, \"prob\": 0.6, \"notes\": \"Moderate recovery and stable margins.\" },\n \"bull\": { \"target_price\": 220.0, \"prob\": 0.2, \"notes\": \"Strong execution and above-consensus growth.\" }\n },\n \"method_notes\": \"DCF with assumed 4% revenue CAGR, 20% EBIT margin, 8.5% WACC, 20x terminal multiple. HOLD due to limited upside vs. risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "equity_research_analyst", "risks": [ "Execution risk in mergers and acquisitions", "Contraction of valuation premiums", "Macroeconomic slowdown reducing demand", "Increased competitive pressures" ], "ticker": "DHR", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Moderate recovery and stable margins.", "target_price": 200 }, "bear": { "prob": 0.2, "notes": "Weak growth and multiple compression.", "target_price": 180 }, "bull": { "prob": 0.2, "notes": "Strong execution and above-consensus growth.", "target_price": 220 } }, "confidence": 0.6, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 20, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "Revenue growth from new products", "impact": "MED", "direction": "POS" }, { "driver": "Margin improvement through efficiencies", "impact": "MED", "direction": "POS" }, { "driver": "Successful acquisition integration", "impact": "HIGH", "direction": "POS" }, { "driver": "Economic downturn impacting demand", "impact": "MED", "direction": "NEG" }, { "driver": "Currency exchange rate volatility", "impact": "LOW", "direction": "NEG" }, { "driver": "Regulatory changes in key markets", "impact": "HIGH", "direction": "POS" } ], "method_notes": "DCF with assumed 4% revenue CAGR, 20% EBIT margin, 8.5% WACC, 20x terminal multiple. HOLD due to limited upside vs. risks. Not investment advice.", "current_price": 196.19, "recommendation": "HOLD", "thesis_bullets": [ "Strong cash flow supports financial flexibility.", "Diversified portfolio mitigates sector-specific risks.", "High valuation multiples limit near-term upside.", "Recent EPS decline indicates growth challenges.", "Acquisition strategy could enhance long-term earnings." ], "target_price_6m": 198, "target_price_12m": 200 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 382, "createdAt": "2026-04-09T05:20:25.839Z", "usage": { "inputTokens": 2034, "outputTokens": 3501, "costUsd": 0.00204 } }, { "id": "cmnr13c380399p658ex0wupsr", "runId": "cmnr13c360396p658bwt8lhuw", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research Analyst AI\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"DHR\",\n \"currency\": \"USD\",\n \"current_price\": 196.19,\n \"target_price_6m\": 212.00,\n \"target_price_12m\": 228.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.72,\n \"thesis_bullets\": [\n \"Bioprocessing destocking cycle is nearing completion, paving the way for volume recovery.\",\n \"Cepheid's molecular diagnostics platform remains a dominant leader in high-growth segments.\",\n \"Strong balance sheet and free cash flow support continued accretive M&A strategy.\",\n \"Danaher Business System (DBS) continues to drive operational efficiency and margin expansion.\",\n \"Valuation is attractive relative to historical averages following recent sector-wide pullbacks.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Bioprocessing order book recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"China life sciences market stabilization\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Cepheid test menu expansion\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Interest rate environment for M&A\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"R&D spending by biotech customers\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operational margin improvement via DBS\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Prolonged funding constraints for early-stage biotech firms.\",\n \"Geopolitical tensions impacting supply chains in China.\",\n \"Integration risks from large-scale acquisitions like Abcam.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.065,\n \"ebit_margin_target\": 0.28,\n \"wacc\": 0.085,\n \"terminal_multiple\": 22.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 178.00,\n \"prob\": 0.2,\n \"notes\": \"Weak biotech funding and China macro headwinds persist throughout the year.\"\n },\n \"base\": {\n \"target_price\": 228.00,\n \"prob\": 0.6,\n \"notes\": \"Steady recovery in bioprocessing and mid-single digit organic growth realized.\"\n },\n \"bull\": {\n \"target_price\": 265.00,\n \"prob\": 0.2,\n \"notes\": \"Rapid bioprocessing rebound and significant accretive M&A deployment occurs.\"\n }\n },\n \"method_notes\": \"Valuation based on 25x forward P/E and DCF analysis. BUY rating reflects 16.2% expected return as bioprocessing headwinds fade and margins stabilize. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "Equity Research Analyst AI", "risks": [ "Prolonged funding constraints for early-stage biotech firms.", "Geopolitical tensions impacting supply chains in China.", "Integration risks from large-scale acquisitions like Abcam." ], "ticker": "DHR", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady recovery in bioprocessing and mid-single digit organic growth realized.", "target_price": 228 }, "bear": { "prob": 0.2, "notes": "Weak biotech funding and China macro headwinds persist throughout the year.", "target_price": 178 }, "bull": { "prob": 0.2, "notes": "Rapid bioprocessing rebound and significant accretive M&A deployment occurs.", "target_price": 265 } }, "confidence": 0.72, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.065, "terminal_multiple": 22, "ebit_margin_target": 0.28 }, "key_drivers": [ { "driver": "Bioprocessing order book recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "China life sciences market stabilization", "impact": "MED", "direction": "POS" }, { "driver": "Cepheid test menu expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Interest rate environment for M&A", "impact": "MED", "direction": "NEG" }, { "driver": "R&D spending by biotech customers", "impact": "HIGH", "direction": "POS" }, { "driver": "Operational margin improvement via DBS", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on 25x forward P/E and DCF analysis. BUY rating reflects 16.2% expected return as bioprocessing headwinds fade and margins stabilize. Not investment advice.", "current_price": 196.19, "recommendation": "BUY", "thesis_bullets": [ "Bioprocessing destocking cycle is nearing completion, paving the way for volume recovery.", "Cepheid's molecular diagnostics platform remains a dominant leader in high-growth segments.", "Strong balance sheet and free cash flow support continued accretive M&A strategy.", "Danaher Business System (DBS) continues to drive operational efficiency and margin expansion.", "Valuation is attractive relative to historical averages following recent sector-wide pullbacks." ], "target_price_6m": 212, "target_price_12m": 228 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-flash-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 13115, "createdAt": "2026-04-09T05:20:25.839Z", "usage": { "inputTokens": 2391, "outputTokens": 808, "costUsd": 0.014478 } }, { "id": "cmnr13c380397p658qn5nnkpe", "runId": "cmnr13c360396p658bwt8lhuw", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"DHR\",\"currency\":\"USD\",\"current_price\":196.19,\"target_price_6m\":186,\"target_price_12m\":188,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"High-quality recurring franchises support resilient cash generation through softer end-market cycles.\",\"Bioprocessing normalization and cautious pharma spending keep near-term organic growth subdued.\",\"DBS productivity, pricing, and mix can rebuild margins as volumes recover.\",\"Balance sheet and free cash flow preserve optionality for disciplined bolt-on acquisitions.\",\"At ~27x forward earnings, valuation already prices much of the recovery.\"],\"key_drivers\":[{\"driver\":\"Bioprocessing demand recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pharma and biotech spending caution\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Diagnostics utilization trends\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"DBS productivity savings\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pricing and mix improvement\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"China academic/government demand\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Bolt-on M&A execution\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Rate-driven multiple compression\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Bioprocessing recovery is delayed again.\",\"Pharma funding and capex weaken further.\",\"Valuation compresses as rates stay higher.\",\"M&A integration or execution missteps.\"],\"assumptions\":{\"revenue_cagr_3y\":5.5,\"ebit_margin_target\":22.5,\"wacc\":8.5,\"terminal_multiple\":25},\"scenarios\":{\"bear\":{\"target_price\":160,\"prob\":0.25,\"notes\":\"Recovery stalls and premium multiple contracts.\"},\"base\":{\"target_price\":188,\"prob\":0.5,\"notes\":\"Growth improves modestly but valuation stays disciplined.\"},\"bull\":{\"target_price\":225,\"prob\":0.25,\"notes\":\"Bioprocessing rebounds faster and margins recover sooner.\"}},\"method_notes\":\"Blended forward-earnings, normalized FCF, and scenario analysis using snapshot quote/fundamentals; no sell-side targets used. Some snapshot fundamentals may not fully reconcile internally, so snapshot quote fields were kept authoritative. HOLD fits mixed recovery evidence and ~-4% 12M implied return; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Model Recommendation", "risks": [ "Bioprocessing recovery is delayed again.", "Pharma funding and capex weaken further.", "Valuation compresses as rates stay higher.", "M&A integration or execution missteps." ], "ticker": "DHR", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Growth improves modestly but valuation stays disciplined.", "target_price": 188 }, "bear": { "prob": 0.25, "notes": "Recovery stalls and premium multiple contracts.", "target_price": 160 }, "bull": { "prob": 0.25, "notes": "Bioprocessing rebounds faster and margins recover sooner.", "target_price": 225 } }, "confidence": 0.63, "assumptions": { "wacc": 8.5, "revenue_cagr_3y": 5.5, "terminal_multiple": 25, "ebit_margin_target": 22.5 }, "key_drivers": [ { "driver": "Bioprocessing demand recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Pharma and biotech spending caution", "impact": "HIGH", "direction": "NEG" }, { "driver": "Diagnostics utilization trends", "impact": "MED", "direction": "POS" }, { "driver": "DBS productivity savings", "impact": "MED", "direction": "POS" }, { "driver": "Pricing and mix improvement", "impact": "MED", "direction": "POS" }, { "driver": "China academic/government demand", "impact": "MED", "direction": "NEG" }, { "driver": "Bolt-on M&A execution", "impact": "LOW", "direction": "POS" }, { "driver": "Rate-driven multiple compression", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended forward-earnings, normalized FCF, and scenario analysis using snapshot quote/fundamentals; no sell-side targets used. Some snapshot fundamentals may not fully reconcile internally, so snapshot quote fields were kept authoritative. HOLD fits mixed recovery evidence and ~-4% 12M implied return; not investment advice.", "current_price": 196.19, "recommendation": "HOLD", "thesis_bullets": [ "High-quality recurring franchises support resilient cash generation through softer end-market cycles.", "Bioprocessing normalization and cautious pharma spending keep near-term organic growth subdued.", "DBS productivity, pricing, and mix can rebuild margins as volumes recover.", "Balance sheet and free cash flow preserve optionality for disciplined bolt-on acquisitions.", "At ~27x forward earnings, valuation already prices much of the recovery." ], "target_price_6m": 186, "target_price_12m": 188 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_01311e853d20cf540069d7581dc878819092df2e63c5174b09", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 53597, "createdAt": "2026-04-09T05:20:25.839Z", "usage": { "inputTokens": 2305, "outputTokens": 2896, "costUsd": 0.044578 } }, { "id": "cmnr13c38039ap658qcwjatzo", "runId": "cmnr13c360396p658bwt8lhuw", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Fundamental Valuation Model\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"DHR\",\n \"currency\": \"USD\",\n \"current_price\": 196.19,\n \"target_price_6m\": 215,\n \"target_price_12m\": 230,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Diversified leadership in life sciences tools\",\n \"Danaher Business System drives margin gains\",\n \"Strong FCF funds strategic M&A pipeline\",\n \"Biopharma recovery offers growth upside\",\n \"Rich valuation caps near-term returns\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Biopharma spending recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"DBS operational improvements\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Strategic M&A execution\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Product innovation pipeline\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Macroeconomic demand weakness\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"High valuation multiple risk\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory compliance costs\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"FX volatility on earnings\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Prolonged biopharma market softness\",\n \"Valuation multiple contraction\",\n \"M&A integration shortfalls\",\n \"Rising competitive pressures\",\n \"Interest rate and FX impacts\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.215,\n \"wacc\": 0.085,\n \"terminal_multiple\": 28\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 165,\n \"prob\": 0.25,\n \"notes\": \"Prolonged end-market weakness triggers de-rating.\"\n },\n \"base\": {\n \"target_price\": 230,\n \"prob\": 0.5,\n \"notes\": \"Moderate growth recovery with stable margins.\"\n },\n \"bull\": {\n \"target_price\": 280,\n \"prob\": 0.25,\n \"notes\": \"Strong demand rebound plus accretive M&A.\"\n }\n },\n \"method_notes\": \"DCF using 6% rev CAGR to 21.5% EBIT margin, 8.5% WACC and 28x terminal. 17% implied 12M return supports BUY on quality vs mixed growth. Consensus noted but not used for targets. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Fundamental Valuation Model", "risks": [ "Prolonged biopharma market softness", "Valuation multiple contraction", "M&A integration shortfalls", "Rising competitive pressures", "Interest rate and FX impacts" ], "ticker": "DHR", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate growth recovery with stable margins.", "target_price": 230 }, "bear": { "prob": 0.25, "notes": "Prolonged end-market weakness triggers de-rating.", "target_price": 165 }, "bull": { "prob": 0.25, "notes": "Strong demand rebound plus accretive M&A.", "target_price": 280 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.06, "terminal_multiple": 28, "ebit_margin_target": 0.215 }, "key_drivers": [ { "driver": "Biopharma spending recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "DBS operational improvements", "impact": "HIGH", "direction": "POS" }, { "driver": "Strategic M&A execution", "impact": "MED", "direction": "POS" }, { "driver": "Product innovation pipeline", "impact": "MED", "direction": "POS" }, { "driver": "Macroeconomic demand weakness", "impact": "MED", "direction": "NEG" }, { "driver": "High valuation multiple risk", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory compliance costs", "impact": "LOW", "direction": "NEG" }, { "driver": "FX volatility on earnings", "impact": "MED", "direction": "NEG" } ], "method_notes": "DCF using 6% rev CAGR to 21.5% EBIT margin, 8.5% WACC and 28x terminal. 17% implied 12M return supports BUY on quality vs mixed growth. Consensus noted but not used for targets. not investment advice.", "current_price": 196.19, "recommendation": "BUY", "thesis_bullets": [ "Diversified leadership in life sciences tools", "Danaher Business System drives margin gains", "Strong FCF funds strategic M&A pipeline", "Biopharma recovery offers growth upside", "Rich valuation caps near-term returns" ], "target_price_6m": 215, "target_price_12m": 230 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "4ac1f6f2-57b3-9d88-8f67-702529eb3836", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 21068, "createdAt": "2026-04-09T05:20:25.839Z", "usage": { "inputTokens": 2644, "outputTokens": 3971, "costUsd": 0.067497 } } ] } }